Chin RegressionPhase 4NCT07777926
Evaluation of Filler Injection for Chin Profile Enhancement
A Phase 4 study testing HA Filler in people with Chin Regression and Chin Asymmetry, run by University of Pennsylvania at 1 site in United States.
Trial summary
The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days. The primary aim of the study is to quantify volume change of the lower face rea over time after injection of filler. Read more about this study
- Who is it for?
- Ages 22 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Chin Regression, Chin Asymmetry, Jawline Contour Deficit
- What is being tested?
- HA Filler
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Sep 2026to 1 Dec 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 22-55
- Patients interested in chin profile enhancement.
- Participants must sign the informed consent form.
Who cannot join
- Prior filler for facial contouring
- Filler injection within the past 12 months or during duration of study
- Prior facial cosmetic surgery (i.e.. facelift)
- Prior facial trauma (i.e.. orbital fracture)
- Pregnant or breastfeeding at the time of injection (initial visit)
- Planned dental work within next 2 weeks
- The following contraindications: patients with known hypersensitivity or severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies, gram-positive bacterial protein allergies, lidocaine allergies or other local anesthetics of the amide type
- Patients with known bleeding disorders
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Penn Medicine
Philadelphia, Pennsylvania, 19104
About this study
Official title: 3-Dimensional Volumetric Analysis of a Hyaluronic Filler Injection for Chin Profile Enhancement
The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days.
The primary aim of the study is to quantify volume change of the lower face rea over time after injection of filler. The secondary aim is to collect patient related outcomes (PROs) via FACE-Q.
Read more
Participants will receive hyaluronic acid filler injections (Restylane Lyft(for contouring of the chin. Each patient will receive FDA approved dosages of filler to the lower face region to treat chin regression or chin contouring, as per FDA approved indications.
Prior to injections patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 moths for re-imaging.
- Conditions
- Chin Regression, Chin Asymmetry, Jawline Contour Deficit
- Being tested
- HA Filler
- Keywords
- jaw, Hyaluronic Acid, HA filler, Hyaluronic Acid filler, Filler, Cosmetic, face, dermal filler, chin, jawline
- Medical subject headings
- Facies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HA FillerDrug
Patients will receive FDA approved dosages of filler to the lower face region to treat chin regression or contour the chin, as per FDA approved indications. Patients are limited to the maximum recommended injected dose per patient for the initial and re-treatment (touch-up) injections of 4 mL. The injected volume per injection site should not exceed 2mL, the maximum volume studied and established by the manufacturer. Prior to injections, patients will be imaged with 3-dimensional photogrammetry and take a validated survey questionnaire (FACE-Q). Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging and FACE-Q survey completion.
| Study group | Role | What they receive |
|---|---|---|
| Filler | Experimental | HA filler to chin region Receives: Drug: HA Filler |
What is being measured
The primary outcome is the main question the study is designed to answer.
Volume change of the lower face area at 90 days post-intervention
3D-images will be collected to determine change in volume from baseline (pre-intervention) to post-intervention (90 days)
Measured: 90 days
Secondary outcomes (1)
Patient Reported Outcomes
Patient-reported outcomes (PROs) will be assessed using FACE-Q questionnaires (FACE-Q), an aesthetics validated survey questionnaire, including appearance, satisfaction, psychological well-being, and treatment outcome domains. FACE-Q scores are transformed to a standardized scale ranging from 0 to 100, with higher scores generally indicating more favorable patient-reported outcomes within the measured domain.
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start30 Sep 2026 (estimated)
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chin RegressionStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ivona Percec, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07777926
- Sponsor's protocol ID
- IRB#26-6336
- Status last verified
- Aug 2026
- First submitted
- 21 Jul 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 3-Dimensional Volumetric Analysis of a Hyaluronic Filler Injection for Chin Profile Enhancement
- ClinicalTrials.gov ID
- NCT07777926
- Acronym / sponsor ID
- IRB#26-6336
- Conditions
- Chin Regression, Chin Asymmetry, Jawline Contour Deficit
- Keywords
- jaw, Hyaluronic Acid, HA filler, Hyaluronic Acid filler, Filler, Cosmetic, face, dermal filler
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Study start
- 30 Sep 2026 (estimated)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 20 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days.
The primary aim of the study is to quantify volume change of the lower face rea over time after injection of filler. The secondary aim is to collect patient related outcomes (PROs) via FACE-Q.
Participants will receive hyaluronic acid filler injections (Restylane Lyft(for contouring of the chin. Each patient will receive FDA approved dosages of filler to the lower face region to treat chin regression or chin contouring, as per FDA approved indications.
Prior to injections patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 moths for re-imaging.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Filler | Experimental | Drug: HA FillerHA filler to chin region |
Who may qualify
- Ages
- 22 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age 22-55
- Patients interested in chin profile enhancement.
- Participants must sign the informed consent form.
Key exclusion criteria (8 listed)
- Prior filler for facial contouring
- Filler injection within the past 12 months or during duration of study
- Prior facial cosmetic surgery (i.e.. facelift)
- Prior facial trauma (i.e.. orbital fracture)
- Pregnant or breastfeeding at the time of injection (initial visit)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HA FillerPatients will receive FDA approved dosages of filler to the lower face region to treat chin regression or contour the chin, as per FDA approved indications. Patients are limited to the maximum recommended injected dose per patient for the initial and re-treatment (touch-up) injections of 4 mL. The injected volume per injection site should not exceed 2mL, the maximum volume studied and established by the manufacturer. Prior to injections, patients will be imaged with 3-dimensional photogrammetry and take a validated survey questionnaire (FACE-Q). Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging and FACE-Q survey completion. | Drug | Filler |
Primary outcome
Volume change of the lower face area at 90 days post-intervention
Time frame: 90 days
3D-images will be collected to determine change in volume from baseline (pre-intervention) to post-intervention (90 days)
1 secondary outcome
Patient Reported Outcomes
Time frame: 90 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing HA Filler in people with Chin Regression and Chin Asymmetry, run by University of Pennsylvania at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aamirah McCutchen (215-360-0652, aamirah.mccutchen@pennmedicine.upenn.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Volume change of the lower face area at 90 days post-intervention (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.